NLS Pharmaceutics Announces Reverse Share Split and Merger with Kadimastem
ByAinvest
Wednesday, Oct 29, 2025 6:03 am ET1min read
NLSP--
NLS Pharmaceutics is undergoing a reverse share split, increasing the value of each share by 10 times. The new trading symbol will be NCEL, and the new name will be NewcelX Ltd. The merger with Kadimastem Ltd. is expected to close soon, and trading will begin on October 31, 2025. The new CUSIP number will be H5835A109.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet